Cox-lox inhibition: Current evidence for an emerging new therapy

International Journal of Clinical Practice

Volumn 57, Issue 4, 2003, Pages 301-304

  Skelly, Maeve M ^a   Hawkey, C J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; LEUKOTRIENE; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MONTELUKAST; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTHRITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HUMAN; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; REVIEW;

ACETIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ARTHRITIS; CLINICAL TRIALS, PHASE III; CYCLOOXYGENASE INHIBITORS; DOGS; HUMANS; INTESTINAL MUCOSA; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MODELS, ANIMAL; PEPTIC ULCER; PROSTAGLANDINS; PYRROLES; RATS; SHEEP;

EID: 0037527546     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-535.
2. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7566.
3. Nickerson-Nutter CL, Medvedeff ED. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum 1996; 39: 515-521.
4. Laufer S. Redox inhibitors: discovery and development of ML3000. Inflammopharmacology 2001; 9: 101-112.
5. Laufer SA, Augustin J, Dannhardt G, Kiefer W. (6,7-diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Medicinal Chem 1994; 37: 1894-1897.
6. Laufer S, Tries S, Augustin J, Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittel Forschung 1994; 44(1): 629-636.
7. 4 in the anormal function of human subchondral osteoarthritic osteoblasts: effects of the combined inhibition of cyclooxygenase and 5-lipoygenase (5-LO) by licofelone (ML-3000). Ann Rheum Dis 2002; 61: THU0199.
8. Abraham WM, Laufer S, Tries S. The effects of ML 3000 on antigen-induced responses in sheep. Pulm Pharmacol Ther 1997; 10: 167-173.
9. Gay RE, Neidhart M, Pataky F et al. Dual inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J Rheumatol 2001; 28: 2060-2065.
10. Jovanovic DV, Fernandes JC, Martel-Pelletier J et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Arthritis Rheum 2001; 44: 2320-2330.
11. Pelletier JP, Fernandes JC, Jolicoeur F-C et al. The in vivo inhibition of cylooxygenase and 5-lipoxygenase by licofelone (ML-3000) reduces the progression of experimental osteoarthritis: suppression of collagenase-11 and interleukin-1β synthesis. Ann Rheum Dis 2002; 61: THU0191.
12. Pelletier JP, Boileau C, Jouzeau JY et al. Licofelone (ML-3000), a dual inhibitor of both 5-lipoxygenase and cyclooxygenases, reduces the level of cartilage chondrycyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. Ann Rheum Dis 2002; 61: THU0198.
13. Reginster J, Bias P, Buchner A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Ann Rheum Dis 2002; 61: THU0189.
14. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 742-747.
15. Kapui Z, Boer K, Rozsa I et al. Investigations of indomethacin-induced gastric ulcer in rats. Drug Res 1993; 43: 767-771.
16. Rainsford KD. Inhibition by leukotriene inhibitors and calcium and platelet activating factor antagonists of acute gastric and intestinal damage in arthritic rats and in cholinomimetic treated mice. J Pharm Pharmacol 1999; 51: 331-339.
17. Rainsford KD. Leukotrienes in the pathogenesis of NSAID-induced gastric intestinal mucosal damage. Agents Actions 1993; 39: C24-C26.
18. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16: 227-240.
19. Sala A, Folco G. Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation? Biochem Biophys Res Commun 2001; 283: 1003-1006.
20. Wallace JL, Carter L, McKnight W et al. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 1994; 271: 525-531.
21. Trevethick MA, Clayton NM, Bahl AK et al. Leukotrienes do not contribute to the pathogenesis of indomethacin-induced ulceration of the gastric antrum in the fed rat. Agents Actions 1994; 41: 179-183.
22. Lee M, Feldman M. Nonessential role of leukotrienes as mediators of acute gastric mucosal injury induced by aspirin in rats. Dig Dis Sci 1992; 37: 1282-1287.
23. Laufer S, Tries S, Augustin J et al. Gastrointestinal tolerance of [2,2-Diomethyl-6-(4-chlorophenyl-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the eat. Arzneimittel-Forschung 1994; 44(II): 1329-1333.
24. Fiorucci S, Distrutti E, Mencarelli A et al. A dual cyclo- and lipooxygenase inhibitor, ML3000 spares gastric mucosa in aspirin-treated rats. Gut 2001; 49(suppl III).
25. Klesser B, Bias P, Buchner A. Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after four weeks of treatment. Ann Rheum Dis 2002; 61: THU0243.
26. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442.
27. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofeCOXib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.